Drug intelligence / Profile preview

LS_01

Development stage: Preclinical
Lead developer: LentiStem Biotech
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

LS_01 is a preclinical-stage chimeric antigen receptor T-cell (CAR-T) therapy being developed by LentiStem Biotech for the treatment of relapsed or refractory (r/r) lymphomas. The therapy utilizes LentiStem's proprietary TCR-like platform, which is designed to enhance the targeting and efficacy of the CAR-T cells. LS_01 specifically targets the CD19 antigen, a well-validated biomarker for B-cell malignancies. As the lead asset in LentiStem's pipeline, LS_01 aims to provide a next-generation cell therapy option for patients with B-cell lymphomas who have failed standard treatments.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on LS_01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LS_01.

Explore the full profile